register

ESG

Hepatitis Australia announces new CEO

Health Industry Hub | March 6, 2020 |

Hepatitis Australia has appointed Carrie Fowlie as its incoming Chief Executive Officer.

Following the retirement of Helen Tyrrell at the beginning of February, Hepatitis Australia undertook a rigorous recruitment process to identify the person to take over the operational leadership of the organisation and work closely with the Board.

Hepatitis Australia President, A/Prof. Grant Phelps said, “the Board is delighted that Carrie has accepted the position of CEO.  Carrie brings deep experience and knowledge of the sector and is well known to and highly regarded by many who have worked with Hepatitis Australia.”

“Carrie is very well positioned to assist the Board and staff of Hepatitis Australia to continue to drive towards improving the lives of people with hepatitis B and hepatitis C and our vison of an end to viral hepatitis in Australia”

Carrie heads to Hepatitis Australia with almost two decades of peak body experience.

Carrie has extensive representational experience at the national and international level. Her work with elected officials and their offices, in parliaments, at the United Nations and with government officials has resulted in policies that are consistent with the evidence and the priorities of the constituencies she has represented.

Carrie Fowlie said, “the leadership of Hepatitis Australia with its members, affected communities, the sector and allies over the past decade has been transformative.”

“What an extraordinary opportunity, working together to achieve a shared goal of eliminating viral hepatitis by 2030.”

“I look forward to contributing to the health and wellbeing and strengthening the voices of around 400,000 Australians living with hepatitis B or hepatitis C and those who represent them.”

Acting CEO, Kevin Marriott says, “the staff team at Hepatitis Australia is excited to welcome Carrie and we look forward to her leadership and guidance into the future.

Carrie Fowlie will formally commence with Hepatitis Australia in mid-April, 2020.

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News - MedTech & Diagnostics

PL reforms deliver $1 billion in savings but patients are yet to see the benefit

PL reforms deliver $1 billion in savings but patients are yet to see the benefit

Health Industry Hub | August 13, 2026 |

The final evaluation of the Prescribed List (PL) reforms has delivered a mixed verdict on one of the private health […]

More


News - Pharmaceuticals

Lilly global CEO takes aim at PBS over Mounjaro price fight - David Ricks

Lilly global CEO takes aim at PBS over Mounjaro price fight

Health Industry Hub | August 13, 2026 |

Eli Lilly’s global CEO has accused the Pharmaceutical Benefits Scheme (PBS) of failing to keep pace with a new era […]

More


News - Pharmaceuticals

Cheap old drug enters MS PBS review as access battle continues

Cheap old drug enters MS PBS review as access battle continues

Health Industry Hub | August 13, 2026 |

The Department of Health has outlined the scope and timelines of the Rapid review of PBS medicines for relapsing-remitting multiple […]

More


News - MedTech & Diagnostics

The piss test, missed diagnoses and the dialysis crunch: Kidney Action Week

The piss test, missed diagnoses and the dialysis crunch: Kidney Action Week

Health Industry Hub | August 13, 2026 |

Kidney Health Australia is taking an unconventional approach to a serious health issue, launching a national media campaign during Kidney […]

More


This content is copyright protected. Please subscribe to gain access.